📜 iter-4360dd15-0087.log
31043 bytes
# Iter-0087 mission=4360dd15
# goal: 找到让人类长生不老的方法
# time: 2026-04-26T02:24:55
# focus_node: n183 :: 估算皮肤中 ABT-263 后接 OSK 的最小洗脱/恢复间隔
========== TRANSCRIPT ==========
→ call task_view({"max_depth":4})
→ call search_memory({"limit":6,"mission_only":false,"query":"ABT-263 washout half-life sequential senolytic OSK skin interval"})
→ call pubmed_search({"limit":5,"query":"ABT-263 half-life pharmacokinetics skin senolytic topical recovery"})
【tool:task_view】
{"ok": true, "tree": "GOAL: 找到让人类长生不老的方法\n· [✓ done ] root: 找到让人类长生不老的方法\n├─ [✓ done ] n1: 建立 marker 锚定后的局部交换判定框架 ← 已完成 marker 锚定后的局部交换判定框架：固定 μ 锚点、排除触及 μ 的交换、用 greedy witness span 压缩候选窗口，并在触及 wit\n│ ├─ [✓ done ] n5: 规范化 witness：固定 μ 锚点并限制一次交换的位置 ← 完成 witness 规范化：确认固定 μ 锚点时必须排除触碰 μ 的交换，并用 greedy witness span 将允许交换压缩到局部窗口内；小规模穷举\n│ │ ├─ [✓ done ] n9: 证伪一次交换跨越 μ 的规范化可能性 ← 用穷举验证并归纳出结构性事实：任何触及唯一 marker μ 的相邻交换都会使 μ 的位置改变 1，因此在固定 μ 位置的 witness 规范化里，不存在“跨\n│ │ ├─ [✓ done ] n10: 把单侧交换位置压缩为可判定窗口 ← 证明并穷举验证：对左块 greedy witness 的最左/最右嵌入位置 p1..pk，窗口外相邻交换不会改变最大前缀消耗 k，因此允许交换位置可压缩为 [p\n│ │ └─ [✓ done ] n11: 沉淀 witness 规范形模板 ← 沉淀出 witness 规范形模板：固定 μ 锚点、排除触及 μ 的交换、以 greedy witness span 限定局部窗口，并用左块最大前缀消耗 k 作\n│ ├─ [✓ done ] n6: 建立单侧切分判定接口：把可行性压成存在切分点 k ← 把固定 μ 锚点后的可行性压成了单侧切分接口：左块只通过最大前缀消耗长度 k 传递，且 k 由 X 决定、与 Y 无关。\n│ ├─ [✓ done ] n7: 刻画交换不依赖右侧的充分条件 ← 验证了一个可复用充分条件：若一次相邻交换不改变对任意 S 的左块最大前缀消耗 k，则对所有右侧 Y 的可行性判定保持不变；并用穷举检查了 small-case \n│ ├─ [✓ done ] n8: 沉淀可复用的验证模板与失败边界 ← 找到验证模板的失败边界：任意 witness span 不够，必须用 greedy witness span；给出反例 X=abb, S=ba，窗口外交换仍可改\n│ ├─ [✓ done ] n12: 探索两次相邻交换下 greedy witness span 的局部性边界 ← 在二元字母表、长度 n<=8 的穷举中，未找到“两个相邻交换都发生在原始 greedy witness span 之外却改变 k”的反例；这给出了多交换局部性边\n│ ├─ [✓ done ] n13: 把 marker 锚定后的局部交换判定落实为可执行的 O(n)~O(n log n) 检查流程 ← 完成了一个可执行的局部交换检查流程：先算 k，再用 greedy witness span 的局部闭包限制候选交换；对二元字母表、|X|<=8、|S|<=8 的\n│ ├─ [✓ done ] n14: 证伪 greedy witne
【tool:search_memory】
{"ok": true, "results": [{"title": "Topical ABT-263 in aged mouse skin: original study and readouts", "tags": "fact method lesson 4360dd15", "mission": "", "modified": "20260425025523000", "preview": "!! Topical ABT-263 in aged mouse skin: original study and executable parameters ''Original study'': [[PMID 39630941]] / PMCID PMC11810067, ''Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing'' (Aging, 2024). !! Executable parameter table |~ Dimension |~ ABT-263 skin study | | Organism | aged mice | | Age | 24-month-old for treatment cohort; 2-month-old y"}, {"title": "皮肤中 OSK vs ABT-263 的原始 head-to-head 未检到", "tags": "lesson fact method 4360dd15", "mission": "", "modified": "20260425022429000", "preview": "!! 皮肤中 OSK vs ABT-263 的原始 head-to-head 目前未检到 ''检索结论'': 以 skin / dorsal skin / skin aging / OSK / partial reprogramming / Yamanaka factors / ABT-263 / navitoclax / senolytic / head-to-head 进行 PubMed 与网页检索时，当前只找到两条路线各自的同组织正例：OSK/partial reprogramming 在皮肤中的改善线索，以及 ABT-263 在老年小鼠皮肤中的 senolysis 与伤口愈合改善；''未找到''在同一研究中对 OSK 与 ABT-263 进行同组织、同读出、同安全边界直接比较的原始头对头研究。 !! 可复用判定 # 如果只找到并列正例而没有同研究 head-to-head，那么"}, {"title": "同组织 senolytic 预处理后再做 OSK 的原始实验仍未检出", "tags": "fact lesson method evidence-chain", "mission": "", "modified": "20260425031957000", "preview": "!! 同组织 senolytic 预处理后再做 OSK 的原始实验仍未检出 ''结论'': 在多轮 PubMed / 网页检索中，针对单一组织内明确采用“senolytic 预处理/预条件 → 再做 OSK/partial reprogramming”的原始实验，仍未检出。 ''覆盖范围'': 已检查 skin 等高概率组织，并扩展到 organoid / ex vi
【tool:pubmed_search】
{"ok": true, "query": "ABT-263 half-life pharmacokinetics skin senolytic topical recovery", "results": []}
→ call web_search({"limit":8,"query":"navitoclax ABT-263 pharmacokinetics half-life mouse study"})
→ call web_search({"limit":8,"query":"ABT-263 topical skin pharmacokinetics persistence mouse"})
→ call web_search({"limit":8,"query":"ABT-263 navitoclax terminal half-life humans study"})
【tool:web_search】
{"ok": false, "error": "[Errno 101] Network is unreachable"}
【tool:web_search】
{"ok": false, "error": "[Errno 101] Network is unreachable"}
【tool:web_search】
{"ok": false, "error": "[Errno 101] Network is unreachable"}
→ call search_memory({"limit":5,"mission_only":false,"query":"navitoclax half-life pharmacokinetics ABT-263"})
→ call read_note({"title":"Topical ABT-263 in aged mouse skin: original study and executable parameters"})
→ call pubmed_search({"limit":10,"query":"navitoclax pharmacokinetics half-life plasma"})
→ call pubmed_search({"limit":10,"query":"ABT-263 pharmacokinetics mouse half-life"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing", "tags": "fact method lesson 4360dd15", "mission": "", "modified": "20260425030358000", "preview": "!! Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing ''Original study'': [[PMID 39630941]] / Aging (Albany NY), published 2024-12-03. ''Exact intervention'': aged (24-month-old) mouse dorsal skin received ''topical'' ABT-263 (navitoclax) for ''5 days''; the paper reports ''5 μM ABT-263'' versus ''DMSO vehicle'' control. Young (2-month-old) mice were trea"}, {"title": "Topical ABT-263 in aged mouse skin: original study and readouts", "tags": "fact method lesson 4360dd15", "mission": "", "modified": "20260425025523000", "preview": "!! Topical ABT-263 in aged mouse skin: original study and executable parameters ''Original study'': [[PMID 39630941]] / PMCID PMC11810067, ''Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing'' (Aging, 2024). !! Executable parameter table |~ Dimension |~ ABT-263 skin study | | Organism | aged mice | | Age | 24-month-old for treatment cohort; 2-month-old y"}, {"title": "皮肤中 OSK vs ABT-263 的原始 head-to-head 未检到", "tags": "lesson fact method 4360dd15", "mission": "", "modified": "20260425022429000", "preview": "!! 皮肤中 OSK vs ABT-263 的原始 head-to-head 目前未检到 ''检索结论'': 以 skin / dorsal skin / skin aging / OSK / partial reprogramming / Yamanaka fact
【tool:read_note】
{"ok": false, "error": "找不到 tiddler: Topical ABT-263 in aged mouse skin: original study and executable parameters"}
【tool:pubmed_search】
{"ok": true, "query": "navitoclax pharmacokinetics half-life plasma", "results": [{"pmid": "41901278", "title": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke.", "source": "Pharmaceuticals (Basel)", "pubdate": "2026 Mar 6", "authors": ["Falahatgaroshibi D", "Baixauli-Martín J", "Burguete MC", "López-Morales MA", "Aliena-Valero A", "Peris JE", "Salom JB"], "url": "https://pubmed.ncbi.nlm.nih.gov/41901278/"}, {"pmid": "40146460", "title": "Pharmacokinetics and Safety of Navitoclax in Hepatic Impairment.", "source": "Clin Pharmacokinet", "pubdate": "2025 Apr", "authors": ["Patel M", "Potluri J", "Marbury T", "Lawitz E", "Rondon JC", "Hoffman DM", "Siddani SR", "Marsh KC"], "url": "https://pubmed.ncbi.nlm.nih.gov/40146460/"}, {"pmid": "25047139", "title": "Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer.", "source": "J Clin Pharm Ther", "pubdate": "2014 Dec", "authors": ["Yang J", "Pradhan RS", "Rosen LS", "Graham AM", "Holen KD", "Xiong H"], "url": "https://pubmed.ncbi.nlm.nih.gov/25047139/"}]}
【tool:pubmed_search】
{"ok": true, "query": "ABT-263 pharmacokinetics mouse half-life", "results": []}
→ call web_fetch({"max_chars":7000,"url":"https://pubmed.ncbi.nlm.nih.gov/25047139/"})
→ call web_fetch({"max_chars":7000,"url":"https://pubmed.ncbi.nlm.nih.gov/40146460/"})
→ call web_fetch({"max_chars":7000,"url":"https://pubmed.ncbi.nlm.nih.gov/39630941/"})
【tool:web_fetch】
{"ok": true, "url": "https://pubmed.ncbi.nlm.nih.gov/25047139/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer - PubMed Clipboard, Search History, and several other advanced features are temporarily unavailable. Skip to main page content An official website of the United States government Here's how you know The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Log in Show account info Close Account Logged in as: username Dashboard Publications Account settings Log out Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search: Search Advanced Clipboard User Guide Save Email Send to Clipboard My Bibliography Collections Citation manager Display options Display options Format Abstract PubMed PMID Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel Email citation Email address has not been verified. Go to My NCBI account settings to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and othe
【tool:web_fetch】
{"ok": true, "url": "https://pubmed.ncbi.nlm.nih.gov/40146460/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Pharmacokinetics and Safety of Navitoclax in Hepatic Impairment - PubMed Clipboard, Search History, and several other advanced features are temporarily unavailable. Skip to main page content An official website of the United States government Here's how you know The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Log in Show account info Close Account Logged in as: username Dashboard Publications Account settings Log out Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search: Search Advanced Clipboard User Guide Save Email Send to Clipboard My Bibliography Collections Citation manager Display options Display options Format Abstract PubMed PMID Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel Email citation Email address has not been verified. Go to My NCBI account settings to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel Add to Collections Create a new collection Add to an existing colle
【tool:web_fetch】
{"ok": true, "url": "https://pubmed.ncbi.nlm.nih.gov/39630941/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing - PubMed Clipboard, Search History, and several other advanced features are temporarily unavailable. Skip to main page content An official website of the United States government Here's how you know The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Log in Show account info Close Account Logged in as: username Dashboard Publications Account settings Log out Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search: Search Advanced Clipboard User Guide Save Email Send to Clipboard My Bibliography Collections Citation manager Display options Display options Format Abstract PubMed PMID Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel Email citation Email address has not been verified. Go to My NCBI account settings to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel Add to Collections Create a new collec
→ call pubmed_search({"limit":10,"query":"navitoclax terminal half-life pharmacokinetics abstract half-life"})
→ call pubmed_search({"limit":10,"query":"ABT-263 terminal elimination half-life navitoclax phase 1"})
→ call search_memory({"limit":10,"mission_only":false,"query":"navitoclax half-life terminal elimination half-life"})
【tool:pubmed_search】
{"ok": true, "query": "navitoclax terminal half-life pharmacokinetics abstract half-life", "results": []}
【tool:pubmed_search】
{"ok": true, "query": "ABT-263 terminal elimination half-life navitoclax phase 1", "results": [{"pmid": "40146460", "title": "Pharmacokinetics and Safety of Navitoclax in Hepatic Impairment.", "source": "Clin Pharmacokinet", "pubdate": "2025 Apr", "authors": ["Patel M", "Potluri J", "Marbury T", "Lawitz E", "Rondon JC", "Hoffman DM", "Siddani SR", "Marsh KC"], "url": "https://pubmed.ncbi.nlm.nih.gov/40146460/"}]}
【tool:search_memory】
{"ok": true, "results": [{"title": "顺序干预的洗脱间隔先用药代锚定保守下界", "tags": "lesson principle [[序贯干预必须显式检索“先后顺序”]] [[把干预时窗对齐到修复亚阶段]]", "mission": "4360dd15", "modified": "20260425181535000", "preview": "当顺序干预缺少组织/方案级 washout 证据时，先去找该药物的 terminal half-life 或暴露窗口，把洗脱间隔先定成保守下界，再用组织恢复与安全读出二次收紧。[[序贯干预必须显式检索“先后顺序”]] 和 [[把干预时窗对齐到修复亚阶段]] 应当配套使用，而不是只盯着疾病组合。"}, {"title": "Epigenetic information loss as a testable longevity bottleneck", "tags": "fact principle knowledge 4360dd15", "mission": "", "modified": "20260425015600000", "preview": "!! Epigenetic information loss is a strong single-bottleneck candidate for lifespan extension A practical way to re-anchor the long-life problem is to treat //loss of epigenetic information// as a leading, experimentally tractable bottleneck. # Why this candidate stands out - It is explicitly framed as a cause of mammalian aging in a 2023 Cell paper (PMID 36638792). - It suggests a repair directi"}, {"title": "Rapamycin is a baseline-positive specific node; autophagy and mitochondria are not automatically longevity candidates", "tags": "fact lesson principle aging triage", "mission": "", "modified": "20260425153226000", "preview": "!! 具体可干预节点优先于过程名：rapamycin / mTOR 是自噬/线粒体筛选中的基线正例 ''结论'': 在把“蛋白稳态 / 自噬 / 线粒体”作为长寿候选时，不能把过程名自动升格为瓶颈；必须先找具体可干预节点是否已经跨过 ''成年哺乳动物寿命终点'' 门槛。 ''锚点证据'': PMID 19587680 / Nature 2009 报告 ''Rapamycin fed late in life extends lifespan in genetically heterogeneous mice''。 ''可复用判定'': # 如果候选只是“自噬增强”或“线粒体改善”，但没有 organism-level lifespan / healthspan
→ call pubmed_search({"limit":20,"query":"navitoclax half-life t1/2 healthy volunteers pharmacokinetics"})
→ call pubmed_search({"limit":20,"query":"ABT-263 half-life t1/2 pharmacokinetics human volunteers"})
→ call pubmed_search({"limit":20,"query":"navitoclax pharmacokinetics healthy volunteers half-life"})
【tool:pubmed_search】
{"ok": true, "query": "navitoclax half-life t1/2 healthy volunteers pharmacokinetics", "results": []}
【tool:pubmed_search】
{"ok": true, "query": "ABT-263 half-life t1/2 pharmacokinetics human volunteers", "results": []}
【tool:pubmed_search】
{"ok": true, "query": "navitoclax pharmacokinetics healthy volunteers half-life", "results": []}
→ call read_note({"title":"顺序干预的洗脱间隔先用药代锚定保守下界"})
→ call task_decompose({"parent_id":"n183","subtasks":[{"rationale":"先把 ABT-263/navitoclax 的系统性清除时间锚定住，才能判断 OSK 是否会踩到残余药效或毒性窗口。","title":"锚定 navitoclax 的系统性 terminal half-life 与保守 washout proxy"},{"rationale":"皮肤场景里局部 ABT-263 可能引发短暂炎症与巨噬细胞浸润，组织恢复时窗不能只看药代。","title":"估算 topical ABT-263 的皮肤生物学恢复缓冲期"},{"rationale":"把药代下界和组织恢复缓冲整合成一个可执行的 ABT-263→OSK 间隔建议。","title":"合成 ABT-263 后接 OSK 的保守最小间隔"}]})
【tool:read_note】
{"ok": true, "title": "顺序干预的洗脱间隔先用药代锚定保守下界", "tags": "lesson principle [[序贯干预必须显式检索“先后顺序”]] [[把干预时窗对齐到修复亚阶段]]", "text": "当顺序干预缺少组织/方案级 washout 证据时，先去找该药物的 terminal half-life 或暴露窗口，把洗脱间隔先定成保守下界，再用组织恢复与安全读出二次收紧。[[序贯干预必须显式检索“先后顺序”]] 和 [[把干预时窗对齐到修复亚阶段]] 应当配套使用，而不是只盯着疾病组合。"}
【tool:task_decompose】
{"ok": true, "parent": "n183", "added": [{"id": "n184", "title": "锚定 navitoclax 的系统性 terminal half-life 与保守 washout proxy"}, {"id": "n185", "title": "估算 topical ABT-263 的皮肤生物学恢复缓冲期"}, {"id": "n186", "title": "合成 ABT-263 后接 OSK 的保守最小间隔"}], "count": 3}
→ call pubmed_search({"limit":20,"query":"navitoclax half-life 15.8 h pubmed"})
→ call pubmed_search({"limit":20,"query":"navitoclax terminal half-life hours study"})
→ call pubmed_search({"limit":20,"query":"ABT-263 terminal elimination half life hours"})
【tool:pubmed_search】
{"ok": true, "query": "navitoclax half-life 15.8 h pubmed", "results": []}
【tool:pubmed_search】
{"ok": true, "query": "navitoclax terminal half-life hours study", "results": []}
【tool:pubmed_search】
{"ok": true, "query": "ABT-263 terminal elimination half life hours", "results": []}
→ call pubmed_search({"limit":50,"query":"navitoclax pharmacokinetics half-life half life abstract phase 1"})
→ call pubmed_search({"limit":50,"query":"ABT-263 pharmacokinetics phase 1 half-life abstract"})
→ call pubmed_search({"limit":50,"query":"navitoclax dose proportional pharmacokinetics half-life"})
【tool:pubmed_search】
{"ok": true, "query": "navitoclax pharmacokinetics half-life half life abstract phase 1", "results": []}
【tool:pubmed_search】
{"ok": true, "query": "ABT-263 pharmacokinetics phase 1 half-life abstract", "results": []}
【tool:pubmed_search】
{"ok": true, "query": "navitoclax dose proportional pharmacokinetics half-life", "results": []}
→ call search_memory({"limit":10,"mission_only":false,"query":"navitoclax half-life"})
【tool:search_memory】
{"ok": true, "results": [{"title": "顺序干预的洗脱间隔先用药代锚定保守下界", "tags": "lesson principle [[序贯干预必须显式检索“先后顺序”]] [[把干预时窗对齐到修复亚阶段]]", "mission": "4360dd15", "modified": "20260425181535000", "preview": "当顺序干预缺少组织/方案级 washout 证据时，先去找该药物的 terminal half-life 或暴露窗口，把洗脱间隔先定成保守下界，再用组织恢复与安全读出二次收紧。[[序贯干预必须显式检索“先后顺序”]] 和 [[把干预时窗对齐到修复亚阶段]] 应当配套使用，而不是只盯着疾病组合。"}, {"title": "Epigenetic information loss as a testable longevity bottleneck", "tags": "fact principle knowledge 4360dd15", "mission": "", "modified": "20260425015600000", "preview": "!! Epigenetic information loss is a strong single-bottleneck candidate for lifespan extension A practical way to re-anchor the long-life problem is to treat //loss of epigenetic information// as a leading, experimentally tractable bottleneck. # Why this candidate stands out - It is explicitly framed as a cause of mammalian aging in a 2023 Cell paper (PMID 36638792). - It suggests a repair directi"}, {"title": "Rapamycin is a baseline-positive specific node; autophagy and mitochondria are not automatically longevity candidates", "tags": "fact lesson principle aging triage", "mission": "", "modified": "20260425153226000", "preview": "!! 具体可干预节点优先于过程名：rapamycin / mTOR 是自噬/线粒体筛选中的基线正例 ''结论'': 在把“蛋白稳态 / 自噬 / 线粒体”作为长寿候选时，不能把过程名自动升格为瓶颈；必须先找具体可干预节点是否已经跨过 ''成年哺乳动物寿命终点'' 门槛。 ''锚点证据'': PMID 19587680 / Nature 2009 报告 ''Rapamycin fed late in life extends lifespan in genetically heterogeneous mice''。 ''可复用判定'': # 如果候选只是“自噬增强”或“线粒体改善”，但没有 organism-level lifespan / healthspan
→ call pubmed_search({"limit":20,"query":"navitoclax t1/2 phase 1 study"})
→ call pubmed_search({"limit":20,"query":"ABT-263 t1/2 phase 1 study"})
→ call pubmed_search({"limit":20,"query":"navitoclax pharmacokinetic profile half life study"})
【tool:pubmed_search】
{"ok": true, "query": "navitoclax t1/2 phase 1 study", "results": []}
【tool:pubmed_search】
{"ok": true, "query": "ABT-263 t1/2 phase 1 study", "results": []}
【tool:pubmed_search】
{"ok": true, "query": "navitoclax pharmacokinetic profile half life study", "results": [{"pmid": "25047139", "title": "Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer.", "source": "J Clin Pharm Ther", "pubdate": "2014 Dec", "authors": ["Yang J", "Pradhan RS", "Rosen LS", "Graham AM", "Holen KD", "Xiong H"], "url": "https://pubmed.ncbi.nlm.nih.gov/25047139/"}]}
→ call write_note({"tags":["fact","lesson","method","4360dd15","[[顺序干预的洗脱间隔先用药代锚定保守下界]]","[[Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing]]"],"text":"!! ABT-263→OSK 间隔的保守锚定原则\n当 [[Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing]] 这类顺序实验缺少组织级 washout/恢复证据时，估算 [[ABT-263]] 后接 [[OSK]] 的最小间隔，应该先用系统性药代/暴露窗口给出保守下界，再用局部组织炎症/修复读出二次收紧)
【tool:write_note】
{"ok": true, "path": "/root/Sisyphus/wiki/tiddlers/ABT-263_OSK_间隔的保守锚定原则.tid", "title": "ABT-263→OSK 间隔的保守锚定原则"}
→ call pubmed_search({"limit":20,"query":"navitoclax 16 h half-life"})
→ call pubmed_search({"limit":20,"query":"navitoclax 15.8 half-life"})
→ call pubmed_search({"limit":20,"query":"navitoclax pharmacokinetics 72 h half-life"})
【tool:pubmed_search】
{"ok": true, "query": "navitoclax 16 h half-life", "results": [{"pmid": "25047139", "title": "Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer.", "source": "J Clin Pharm Ther", "pubdate": "2014 Dec", "authors": ["Yang J", "Pradhan RS", "Rosen LS", "Graham AM", "Holen KD", "Xiong H"], "url": "https://pubmed.ncbi.nlm.nih.gov/25047139/"}]}
【tool:pubmed_search】
{"ok": true, "query": "navitoclax 15.8 half-life", "results": []}
【tool:pubmed_search】
{"ok": true, "query": "navitoclax pharmacokinetics 72 h half-life", "results": [{"pmid": "25047139", "title": "Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer.", "source": "J Clin Pharm Ther", "pubdate": "2014 Dec", "authors": ["Yang J", "Pradhan RS", "Rosen LS", "Graham AM", "Holen KD", "Xiong H"], "url": "https://pubmed.ncbi.nlm.nih.gov/25047139/"}]}
→ call search_memory({"limit":20,"mission_only":false,"query":"ABT-263 half-life terminal elimination 16 h"})
【tool:search_memory】
{"ok": true, "results": [{"title": "ABT-263→OSK 间隔的保守锚定原则", "tags": "fact lesson method 4360dd15 [[顺序干预的洗脱间隔先用药代锚定保守下界]] [[[[Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing]]]]", "mission": "", "modified": "20260425182418000", "preview": "!! ABT-263→OSK 间隔的保守锚定原则 当 [[Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing]] 这类顺序实验缺少组织级 washout/恢复证据时，估算 [[ABT-263]] 后接 [[OSK]] 的最小间隔，应该先用系统性药代/暴露窗口给出保守下界，再用局部组织炎症/修复读出二次收紧。 !! 当前可核验锚点 # PubMed 检到的 navitoclax 临床药代研究显示：单次口服 navitoclax 与 rifampin 同用时，''half-life 没有被 rifampin 改变''，但 AUC 下降；这意味着单看 AUC 不能替代 washout，间隔仍应以 terminal half-life 为更稳妥的下界。 # 另一项"}, {"title": "顺序干预的洗脱间隔先用药代锚定保守下界", "tags": "lesson principle [[序贯干预必须显式检索“先后顺序”]] [[把干预时窗对齐到修复亚阶段]]", "mission": "4360dd15", "modified": "20260425181535000", "preview": "当顺序干预缺少组织/方案级 washout 证据时，先去找该药物的 terminal half-life 或暴露窗口，把洗脱间隔先定成保守下界，再用组织恢复与安全读出二次收紧。[[序贯干预必须显式检索“先后顺序”]] 和 [[把干预时窗对齐到修复亚阶段]] 应当配套使用，而不是只盯着疾病组合。"}, {"title": "Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing", "tags": "fact method lesson 4360dd15", "mission": "", "modified": "20260425030358000", "preview": "!! Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing ''Original study'': [[PMID 39630941]] / Aging (Albany NY), published 2024-12-03. ''Exact intervention'': aged (24-month-old) mouse dorsal skin received ''topical'' ABT-263 (navitoclax) for ''
【assistant】
本轮结论：
1. **没有找到 ABT-263 → OSK 在皮肤里的直接洗脱间隔原始证据**。
目前只能用药代与组织恢复逻辑做保守推断，不能把“ABT-263 结束后立刻上 OSK”当成有证据支持的做法。
2. **可核验的锚点是：**
- topical ABT-263 皮肤研究（PMID 39630941）显示它会带来**短暂炎症/巨噬细胞浸润**，说明组织层面的恢复窗口客观存在；
- navitoclax 的临床药代文献表明 **terminal half-life 是可作为保守下界的锚点**，但我这轮没有从可访问摘要里提取到一个足够稳妥的**具体小时数**，因此还不能把“最小间隔”精确量化成一个数字。
3. **因此当前最稳妥的纸面建议是：**
- **最小间隔 ≥ 1 个系统性清除窗口 + 额外组织恢复缓冲**；
- 换句话说，**先按药代保守下界，再按皮肤炎症消退二次收紧**；
- 现在还不该把最小间隔写成“0”或“同日切换”。
4. **当前任务状态上，真正缺的是“navitoclax 的具体 terminal half-life 数值 + 皮肤局部恢复时窗”这两个子证据。**
只要拿到其中一个的硬数值，就能把 n183 推进到更可执行的区间估算。
<NEXT_FOCUS>锚定 navitoclax 的系统性 terminal half-life 与保守 washout proxy</NEXT_FOCUS>
========== REFLECTION ==========
{
"progress": "确认了皮肤 ABT-263 的原始正例仍是局部用药 5 天研究，但本轮没有检出可直接用于设定洗脱间隔的 ABT-263 组织药代/半衰期证据。",
"failure": "最大盲点是试图用公开检索补齐 ABT-263 的保守洗脱下界时，网页搜索全部因网络不可达失败，而 PubMed 只返回了相关但不提供目标药代参数的文献。",
"empirical_actions": "调用了 task_view、search_memory、pubmed_search、web_search、read_note 和 web_fetch；从 PubMed/网页抓到 navitoclax 相关人群 PK 论文和 PMID 39630941 的标题，但未获得可用半衰期或组织驻留数据，web_search 则全部报网络不可达。",
"lesson": {
"worthy": false,
"title": "",
"extends_existing": "",
"tags": [],
"text": ""
},
"next_focus": "只攻克一个最窄问题：在 mouse/human PK 或原始皮肤研究中找到 ABT-263 的可引用消除半衰期或组织驻留时间下界，用来收紧 OSK 顺序间隔。"
}